<?xml version="1.0" encoding="UTF-8"?>
<p id="para0016">ECMO has been used successfully to manage patients with severe respiratory failure in previous coronavirus epidemics.
 <xref rid="bib0055" ref-type="bibr">
  <sup>55</sup>
 </xref> Data from the Middle East respiratory syndrome epidemic demonstrated improved survival in patients with severe ARDS supported by venovenous ECMO.
 <xref rid="bib0056" ref-type="bibr">
  <sup>56</sup>
 </xref> A meta-analysis of patients with isolated viral myocarditis, supported by venoarterial (VA)-ECMO, found a similar survival benefit in this group.
 <xref rid="bib0057" ref-type="bibr">
  <sup>57</sup>
 </xref> As a result, elective ECMO cannulation reportedly has been used worldwide to support COVID-19 patients.
 <xref rid="bib0058" ref-type="bibr">58</xref>, 
 <xref rid="bib0059" ref-type="bibr">59</xref>, 
 <xref rid="bib0060" ref-type="bibr">60</xref> In these reports, ECMO was used to provide cardiopulmonary support and preserve end-organ function while allowing for the administration of antiviral and anti-inflammatory therapies.
</p>
